Gene expression signatures of radiation response are specific, durable and accurate in mice and humans.

I am passionate about expanding children's access to mental and behavioral health services through my clinical work and education of medical trainees. I previously practiced General Pediatrics and also had a past career in education (teaching middle and high school sciences). These roles and my experiences as a parent informed my path to a fellowship in Developmental & Behavioral Pediatrics, during which I completed additional training in medical education (earning a certificate as a clinician educator). I now serve as the director of the pediatric residents' Behavior & Development rotation and the co-lead of NC-PAL's education workgroup, providing educational opportunities for primary care clinicians throughout NC. 

As a specialist in Developmental-Behavioral Pediatrics, I provide consultations for children with developmental concerns, including developmental delays, autism, complex ADHD, and academic difficulties. I see patients with known or suspected genetic conditions (including Fragile X Syndrome, Tuberous Sclerosis, Down Syndrome, 22q11 deletion syndrome, Neurofibromatosis, Turner Syndrome, Prader Willi or Angelman Syndrome, Williams Syndrome, and others) who have behavioral concerns or possibly ADHD. 

Dr. Geoffrey S. Ginsburg's research interests are in the development of novel paradigms for developing and translating genomic information into medical practice and the integration of personalized medicine into health care.

My research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution. On the clinical side we are currently conducting approximately 50 different clinical protocols ranging from preparatory regimens, supportive care studies and disease specific protocols. Most of these clinical studies are centered around studies of the sources of stem cells and the methods to improve the long term outcome. There are exploratory protocols for novel therapies such as dendritic cell therapy for several malignancies, antiangiogenesis therapy, graft engineering to prevent graft-versus-host disease and antigen specific T cells or non specific NK cells to prevent relapse. Moreover a strong focus of the program is to develop cord-blood transplantation for adult patients with hematologic malignancies. The laboratory studies center on understanding the immunological events that occur with graft-vs-host disease and methods to prevent this disease. The current efforts focus on understanding murine reconstitution following transplantation, use of a peptide polymer to block MHC class II recognition of minor histocompatibility antigens, use of T cell engineering to prevent graft-versus-host disease at the same time preserving a graft-versus-malignancy effect.

For more information see http://ed-media.mc.duke.edu/BMT.nsf